DE-GRAMONT-FOLFOX2

Regimen

Experimental
FOLFOX (oxaliplatin + infusional 5-FU/LV de Gramont schedule)
Control
5-FU/LV (infusional de Gramont schedule) alone

Population

Metastatic CRC, 1L, previously untreated; foundational trial establishing FOLFOX standard.

Key finding

1L mCRC (unselected): mPFS 9.0 vs 6.2 mo (p=0.0003); ORR 50.7% vs 22.3% (p=0.0001); mOS 16.2 vs 14.7 mo (p=0.12, NS); FOLFOX2 (oxaliplatin 85 mg/m2 + LV5FU2) established oxaliplatin superiority in PFS over 5-FU/LV alone

Source: PMID 10944126

Timeline

    Guideline citations

    • NCCN Colon (p.6)
    • NCCN Rectal (p.6)